Laborie Medical

Laborie operates as a diversified medical-device platform focused on urology, urogynecology, gastroenterology, colorectal care, obstetrics, and neonatal health. Its portfolio spans diagnostic systems, consumables, and minimally invasive therapies rather than a single device category. Products such as the Optilume BPH Catheter System and Optilume Urethral Drug-Coated Balloon give Laborie exposure to both procedural treatment and drug-device combinations, while Solar GI, Nexam Pro, and other diagnostic systems broaden its recurring equipment and consumables base. The JADA acquisition, valued at up to $465 million, adds a major obstetrics asset and demonstrates the company’s willingness to expand beyond its historical pelvic-floor concentration. Laborie’s competitive differentiation is therefore based on breadth, clinical workflow coverage, and the ability to combine diagnosis with treatment across adjacent specialties. The company’s private ownership and acquisition history also make public comparisons of revenue, margins, and valuation difficult.

Laborie’s growth trajectory is defined more by acquisitions and portfolio expansion than by disclosed venture financing. The company recorded one identified private-equity round led by Audax Private Equity in July 2012, with no public amount available. Since then, it has completed or announced at least 13 acquisitions, including Medical Measurement Systems in 2015, Cogentix Medical in 2018, Clinical Innovations in 2019, Pelvalon in 2021, GI Supply and Novonate in 2022-2023, Urotronic in 2023, and JADA System in 2025. The disclosed prices of several transactions total more than $1.48 billion, although this is acquisition expenditure rather than company funding. Product development provides a second growth engine: the Optilume platform has advanced into BPH, urethral stricture, and ureteric applications, with first ENDURE 1 study procedures reported on Oct 28, 2025. Laborie lists an employee range of 501-1,000, while its website describes more than 1,000 employees, indicating continued scale but also a headcount-data discrepancy. The 2025 CEO transition marks a leadership inflection point during this expansion phase.